A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection

  • Akio MiyasakaEmail author
  • Yuichi Yoshida
  • Akiko Suzuki
  • Hironobu Ueda
  • Yoshihiro Morino
  • Yasuhiro Takikawa
Case Report


A 44-year-old woman with chronic hepatitis C virus (HCV) infection was referred by a primary care doctor and admitted to our hospital because of worsening dyspnea on exertion and right atrial and ventricular enlargement. The patient was diagnosed with pulmonary arterial hypertension (PAH) associated with portal hypertension induced by chronic HCV infection. This diagnosis was based on a cardiological examination and findings related to liver cirrhosis with portal hypertension. After the prescription of anti-PAH medicine and a slight improvement in her respiratory symptoms, 12-week direct-acting antiviral (DAA) treatment for HCV was started. Serum HCV RNA levels rapidly decreased and HCV elimination was confirmed 24 weeks after completing DAA treatment. Before confirmation of a sustained virological response at 24 weeks after completing DAA treatment, a remarkable improvement in her cardiac markers was found in a right heart catheter study. This study was performed 6 weeks after the end of DAA administration. Therefore, we considered that HCV infection was involved in the development of PAH and that elimination of HCV by interferon-free treatment was important for this patient.


Pulmonary hypertension HCV infection Portal-pulmonary hypertension Direct-acting antivirals 



Pulmonary hypertension


Pulmonary arterial pressure


Right heart catheterization


Pulmonary arterial hypertension


Portal-pulmonary hypertension




Hepatitis C virus


Direct-acting antiviral


Sustained virological response


New York Heart Association


Brain natriuretic peptide


Computed tomography


Cardiac Index


Signal transducer and activator of transcription 3



We thank Ellen Knapp, PhD, from Edanz Group ( for editing a draft of this manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest in association with the present study.

Human/animal rights

All procedures followed were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed Consent

Informed consent was obtained from the patient in our study.


  1. 1.
    Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonaly hypertension. J Am Coll Cardiol. 2013;62:D42–50.CrossRefGoogle Scholar
  2. 2.
    Galié N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Pediatrics and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.CrossRefGoogle Scholar
  3. 3.
    Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013;144:102–11.CrossRefGoogle Scholar
  4. 4.
    Kimura K, Ohto M, Matsutani S, et al. Relative frequencies of portosystemic pathways and renal shunt formation through the “posterior” gastric vein: portographic study in 460 patients. Hepatology. 1990;12:725–8.CrossRefGoogle Scholar
  5. 5.
    Chen HS, Xing SR, Xu WG, et al. Portopulmonary hypertension in cirrhotic patients: prevalence, clinical features and risk factors. Exp Ther Med. 2013;5:819–24.CrossRefGoogle Scholar
  6. 6.
    Paulin R, Courboulin A, Meloche J, et al. Signal transducers and activators of transcription-3/pim 1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 2011;123:1205–15.CrossRefGoogle Scholar
  7. 7.
    Gong G, Waris G, Tanveer R, et al. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA. 2001;98:9599–604.CrossRefGoogle Scholar
  8. 8.
    Dhillon S, Kaker A, Dosanjh A, et al. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci. 2010;55:1785–90.CrossRefGoogle Scholar
  9. 9.
    Ko T, Hatano M, Nitta D, et al. A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation. Heart Vessels. 2016;31:1206–8.CrossRefGoogle Scholar
  10. 10.
    Tsuchiya H, Kioka H, Ozu K, et al. Interferon therapy exacerbated pulmonary hypertension in a patient with hepatitis C virus infection: pathogenic interplay among multiple risk factors. Intern Med. 2017;56:1061–5.CrossRefGoogle Scholar
  11. 11.
    George PM, Cunningham ME, Galloway-Phillipps N, et al. Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ. 2012;2:501–4.CrossRefGoogle Scholar
  12. 12.
    George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary hypertension. Circ Res. 2014;114:677–88.CrossRefGoogle Scholar
  13. 13.
    Renard S, Borentain P, Salaun E, et al. Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir. Chest. 2016;149:e69–73.CrossRefGoogle Scholar
  14. 14.
    Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557–65.CrossRefGoogle Scholar
  15. 15.
    Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2017. [Epub ahead of print].Google Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  1. 1.Division of Hepatology, Department of Internal MedicineIwate Medical University School of MedicineMoriokaJapan
  2. 2.Division of Cardiology, Department of Internal MedicineIwate Medical University School of MedicineMoriokaJapan

Personalised recommendations